IL-15(N72D)/IL-15Ralpha-sFc Fusion Protein Complex FL115 clinical trials
Also written FL115.
Its developmentBy Suzhou Forlong Biotechnology, step by step5 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses IL-15(N72D)/IL-15Ralpha-sFc Fusion Protein Complex FL115 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the IL-15(N72D)/IL-15Ralpha-sFc Fusion Protein Complex FL115 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- FL115
- 4
Studies by the year they started
5 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Suzhou Forlong Biotechnology Co., Ltd (5)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test IL-15(N72D)/IL-15Ralpha-sFc Fusion Protein Complex FL115.
- Dec 2026A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid TumorsPhase 1/2 · Suzhou Forlong Biotechnology Co., Ltd
- Sep 2027A Study of Subcutaneous FL115 Monotherapy in Participants With Advanced Solid TumorsPhase 1 · Suzhou Forlong Biotechnology Co., Ltd
- Oct 2027A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder CancerPhase 1/2 · Suzhou Forlong Biotechnology Co., Ltd
Studies
Open first, then newest update. How each study uses IL-15(N72D)/IL-15Ralpha-sFc Fusion Protein Complex FL115 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of Subcutaneous FL115 Monotherapy in Participants With Advanced Solid TumorsNot yet recruitingPhase 1Suzhou Forlong Biotechnology Co., LtdNCT07785193Written as FL115
- A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid TumorsRecruitingPhase 1/2Suzhou Forlong Biotechnology Co., LtdNCT07131202Written as FL115+PD-1
- A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder CancerRecruitingPhase 1/2Suzhou Forlong Biotechnology Co., LtdNCT07122414Written as FL115
- A Study of FL115 Monotherapy in Unresectable or Metastatic Solid TumorsActive, not recruitingPhase 1Suzhou Forlong Biotechnology Co., LtdNCT07131189Written as FL115
- First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical StudyCompletedPhase 1Suzhou Forlong Biotechnology Co., LtdNCT06130722Written as FL115